Sun Pharmaceutical IndustriesQ3 FY24

Sun Pharmaceutical Industries Q3 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,870P/E: 36.5Market Cap: ₹4.5L CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 4

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 4
  • India Business: Sun Pharma grew 11.4% in Q3 FY24, outperforming the Indian Pharmaceutical Market (IPM). Growth was driven by both volume and new product launches (~2/3 of growth). The company aims to grow in line with or better than the market, but market-wide volume recovery for next year remains uncertain.
  • U.S. Specialty Business: Strong growth expected, driven by products like Ilumya, CEQUA, and Levulan. Incremental P&L investments planned to support growth, tailored by product and market.
  • Emerging Markets: Underlying constant currency growth was about 5.2% year-on-year in Q3 FY24.
  • Rest of the World: 12.9% sales growth in Q3 FY24, continued investment in pipeline expected.
  • Specialty products, including Ilumya, continue to be in the growth phase, with expectations to sustain momentum.
  • Overall, a growth-oriented budget is planned with investments in sales, marketing, and product development to maintain growth trajectory.

See what Sun Pharmaceutical Industries management said on margin guidance — free account, 30 seconds.

Fundraise plans

  • There is no mention of any current or planned new fundraising through debt or equity in the transcript.
  • Dilip Shanghvi stated that the company is sitting on about $2 billion of cash and cash equivalents plus generating over $1 billion annual cash flow.
  • The company does not have plans to return cash to shareholders via buybacks or dividends because it sees good investment opportunities.
  • The focus is on investing the cash to generate double-digit returns on investment.
  • No indication or discussion of raising new capital through debt or equity was provided during the call.

See what Sun Pharmaceutical Industries management said on order book — free account, 30 seconds.

Capex plans

Yes
  • Sun Pharma is currently sitting on about $2 billion of cash and cash equivalents and generates over $1 billion in annual cash flow.
  • There is no plan to return excess cash to shareholders via buybacks or increased dividends; instead, the company intends to seek appropriate investment opportunities.
  • Recent market corrections have presented interesting investment opportunities that the company aims to work on.
  • The company continues to invest in building its R&D pipeline for both Global Generics and Specialty businesses, with consolidated R&D spend at 6.8% of sales in Q3 FY24.
  • Specialty R&D accounted for 39.2% of total R&D spend in the quarter.
  • There is ongoing development of specialty products such as GL0034 and pipeline progression indicated, with more detailed R&D guidance expected next year.

Track Sun Pharmaceutical Industries — get its next earnings analysis in your feed

How does Sun Pharmaceutical Industries rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature
ThisSun Pharmaceutical Industries
Rev 4Mar 3

How does Sun Pharmaceutical Industries rank in Pharmaceuticals & Biotechnology?

Compare Sun Pharmaceutical Industries against every Pharmaceuticals & Biotechnology company (Q3 FY24) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Others in Pharmaceuticals & Biotechnology this season

  • Lasa Supergeneri (Q2 FY27)

    306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra

  • Themis Medicare (Q2 FY27)

    Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q

  • Panacea Biotec (Q2 FY27)

    September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Biofil Chemicals (Q2 FY27)

    Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →